With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.885279-92-5,1-Boc-1,8-diaza-spiro[4.5]decane,as a common compound, the synthetic route is as follows.
A 40-mL vial was charged with N-(1H-pyrazol-3-yl)acetamide (125 mg, 1.00 mmol, 1.00 equiv), DCM (10 mL), and N,N-diisopropylethylamine (258 mg, 2.00 mmol, 2.00 equiv).4-Nitrophenyl chloroformate (222 mg, 1.10 mmol, 1.10 equiv) in DCM (2 mL) was addeddropwise at 0 C. The resulting solution was stirred for 2 h at room temperature. Then tertbutyl 1,8-diazaspiro[4.5]decane-1-carboxylate (240 mg, 1.00 mmol, 1.00 equiv) was added. The resulting solution was stirred overnight at room temperature and quenched by water (10 mL). The mixture was extracted with DCM (3 x 10 mL) and the organic layers were combined, washed with water (3 x 10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed on a silica gel column to provide 295 mg (75% yield) of tert-butyl 8-(3 -acetamido- 1H-pyrazole- 1 -carbonyl)- 1,8- diazaspiro[4.5]decane-1-carboxylate as a light yellow oil. LCMS (ESI, m/z): 392 [M+H]., 885279-92-5
As the paragraph descriping shows that 885279-92-5 is playing an increasingly important role.
Reference：
Patent; ABIDE THERAPEUTICS, INC.; WEBER, Olivia D.; SHAGHAFI, Michael B.; GRICE, Cheryl A.; JONES, Todd K.; (274 pag.)WO2017/87854; (2017); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem